Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1

Interventions

Tamoxifen 21Radiotherapy 9Chemotherapy, Adjuvant 9Specimen Handling 8Early Intervention, Educational 8Anastrozole 7Neoadjuvant Therapy 6Methods 6Letrozole 6Psychiatric Rehabilitation 5Practice Guidelines as Topic 5Immunohistochemistry 5Counseling 5Biopsy 5Standard of Care 4Mastectomy, Segmental 4Mass Spectrometry 4Magnetic Resonance Spectroscopy 4Gene Expression Profiling 4Educational Status 4Behavior Therapy 4exemestane 3Radiation Dose Hypofractionation 3Radiation 3Brachytherapy 3Watchful Waiting 2Therapeutics 2Telemedicine 2Taxes 2Surveys and Questionnaires 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Carcinoma In Situ × Bexarotene × Breast × Clear all
NCT03323658 2023-01-10

Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer

National Cancer Institute (NCI)

Phase 1 Completed
24 enrolled 12 charts
Breast

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡